Promoted Content
Promoted Content

Find Clinical Drug Pipeline Developments & Deals by RemeGen

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Therapeutic Area filter
    Study Phase filter
      Country filter
        News Type filter
          Company filter
            refresh

            Companies By Therapeutic Area Full Screen

            Development Status Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Disitamab vedotin

            Therapeutic Area: Oncology Product Name: RC48

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 25, 2020

            Details:

            U. S FDA has granted Breakthrough Therapy designation for disitamab vedotin, a novel humanized anti-HER2 antibody drug conjugate, for second-line treatment of patients with HER2+ locally advanced/metastatic urothelial cancer, who had received platinum-based chemotherapy.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Disitamab vedotin

            Therapeutic Area: Oncology Product Name: RC48

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 17, 2020

            Details:

            Results demonstrated a clinically meaningful response and survival benefit for heavily treated patients with unmet need.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Disitamab vedotin

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 29, 2020

            Details:

            The IND clearance for RC48's first US-based trial arrives on the heels of RemeGen's recently completed $100 million plus financing, led by Lilly Asia Ventures and Lake Bleu Capital.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Telitacicept

            Therapeutic Area: Immunology Product Name: Undisclosed

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 15, 2020

            Details:

            US FDA granted Fast Track designation for RC18, for the treatment of systemic lupus erythematosus (SLE). RC18 shows statistically significant improvement for patients at multiple doses.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Telitacicept

            Therapeutic Area: Immunology Product Name: Undisclosed

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Lilly Asia Ventures

            Deal Size: $100.0 million Upfront Cash: Undisclosed

            Deal Type: Financing April 02, 2020

            Details:

            Funds will support clinical trials and commercialization for its autoimmune, oncology and ophthalmology pipeline.